About the investigational drug
The TALLY clinical trial aims to understand if an investigational drug could be safe and potentially effective in impacting CIAS.
This potential treatment is a positive allosteric modulator (potentiator) of the AMPA receptor that represents a mechanistically novel approach to the treatment of CIAS.
https://www.tallyschizophreniatrial.com/EN-US/TallyClinicalTrial.html#about-the-investigation-drug
In an early study involving a small number of patients, it showed a potential to impact cognitive function in patients with CIAS.